文献速递泌尿男性生殖肿瘤

MK-2206对比依维莫司治疗难治性肾细胞癌的随机2期研究

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
PubMed 文献 · Ann Oncol · 2017-01-01

该随机2期研究将43例VEGF治疗难治性肾细胞癌患者按2:1分配至MK-2206组(29例)或依维莫司组(14例),主要终点为无进展生存期(PFS)。首次无效性分析时试验关闭,MK-2206组PFS为3.68个月,依维莫司组为5.98个月;MK-2206未显示优于依维莫司,且DNA修复基因突变与早期疾病进展相关。

要点

  • MK-2206组PFS为3.68个月,依维莫司组为5.98个月,试验在首次无效性分析时关闭。
  • MK-2206组1例完全缓解、3例部分缓解,依维莫司组无缓解;疾病进展为最佳疗效者MK-2206组44.8% vs 依维莫司组14.3%。
  • MK-2206较依维莫司引起更多皮疹和瘙痒,剂量降低者MK-2206组37.9% vs 依维莫司组21.4%。

核心结论

  • VEGF治疗难治性肾细胞癌患者接受MK-2206治疗时观察到 dichotomous 结局,MK-2206未显示优于依维莫司。
  • DNA修复基因突变与早期疾病进展相关,提示DNA修复失调与肾细胞癌更具侵袭性的肿瘤表型相关。

研究设计与样本

  • 随机2期研究,共43例VEGF治疗难治性肾细胞癌患者,按2:1分配至MK-2206组(29例)或依维莫司组(14例),主要终点为无进展生存期(PFS)。

主要发现

  • 试验在首次无效性分析时关闭,观察到的PFS为MK-2206组3.68个月 vs 依维莫司组5.98个月。
  • MK-2206组有1例完全缓解和3例部分缓解,依维莫司组无缓解。
  • 疾病进展为最佳疗效者占MK-2206组的44.8% vs 依维莫司组的14.3%。
  • MK-2206较依维莫司引起显著更多的皮疹和瘙痒,剂量降低发生于MK-2206组的37.9% vs 依维莫司组的21.4%。
  • 基因组分析显示,疾病进展组中57.1%的患者携带有害TP53突变或ATM突变或缺失,而非疾病进展组中无患者携带TP53或ATM缺陷;该小型数据集中未观察到反应预测标志物。

局限性

  • 该数据集较小,未观察到反应预测标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activation of the phosphoinisitide-3 kinase (PI3K) pathway through mutation and constitutive upregulation has been described in renal cell carcinoma (RCC), making it an attractive target for therapeutic intervention. We performed a randomized phase II study in vascular endothelial growth factor (VEGF) therapy refractory patients to determine whether MK-2206, an allosteric inhibitor of AKT, was more efficacious than the mammalian target of rapamycin inhibitor everolimus. PATIENTS AND METHODS: A total of 43 patients were randomized in a 2:1 distribution, with 29 patients assigned to the MK-2206 arm and 14 to the everolimus arm. Progression-free survival (PFS) was the primary endpoint. RESULTS: The trial was closed at the first futility analysis with an observed PFS of 3.68 months in the MK-2206 arm and 5.98 months in the everolimus arm. Dichotomous response rate profiles were seen in the MK-2206 arm with one complete response and three partial responses in the MK-2206 arm versus none in the everolimus arm. On the other hand, progressive disease was best response in 44.8% of MK2206 versus 14.3% of everolimus-treated patients. MK-2206 induced significantly more rash and pruritis than everolimus, and dose reduction occurred in 37.9% of MK-2206 versus 21.4% of everolimus-treated patients. Genomic analysis revealed that 57.1% of the patients in the PD group had either deleterious TP53 mutations or ATM mutations or deletions. In contrast, none of the patients in the non-PD group had TP53 or ATM defects. No predictive marker for response was observed in this small dataset. CONCLUSIONS: Dichotomous outcomes are observed when VEGF therapy refractory patients are treated with MK-2206, and MK-2206 does not demonstrate superiority to everolimus. Additionally, mutations in DNA repair genes are associated with early disease progression, indicating that dysregulation of DNA repair is associated with a more aggressive tumor phenotype in RCC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Jonasch E, Hasanov E, Corn PG, et al. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017. PMID: 28049139. doi:10.1093/annonc/mdw676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。